- Home
- NOG vs GH Comparison
NOG vs GH Comparison
Compare NOG & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOG
- GH
- Stock Information
- Founded
- NOG N/A
- GH 2011
- Country
- NOG United States
- GH United States
- Employees
- NOG N/A
- GH N/A
- Industry
- NOG Oil & Gas Production
- GH Medical Specialities
- Sector
- NOG Energy
- GH Health Care
- Exchange
- NOG Nasdaq
- GH Nasdaq
- Market Cap
- NOG 4.0B
- GH 3.0B
- IPO Year
- NOG N/A
- GH 2018
- Fundamental
- Price
- NOG $34.79
- GH $26.25
- Analyst Decision
- NOG Strong Buy
- GH Strong Buy
- Analyst Count
- NOG 11
- GH 17
- Target Price
- NOG $46.91
- GH $39.31
- AVG Volume (30 Days)
- NOG 1.2M
- GH 2.3M
- Earning Date
- NOG 10-30-2024
- GH 11-04-2024
- Dividend Yield
- NOG 4.92%
- GH N/A
- EPS Growth
- NOG N/A
- GH N/A
- EPS
- NOG 5.69
- GH N/A
- Revenue
- NOG $1,970,876,000.00
- GH $643,810,000.00
- Revenue This Year
- NOG $29.43
- GH $27.01
- Revenue Next Year
- NOG $12.87
- GH $18.30
- P/E Ratio
- NOG $6.00
- GH N/A
- Revenue Growth
- NOG 17.65
- GH 26.20
- 52 Week Low
- NOG $31.13
- GH $15.81
- 52 Week High
- NOG $43.80
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- NOG 35.22
- GH 47.12
- Support Level
- NOG $33.17
- GH $24.55
- Resistance Level
- NOG $40.56
- GH $25.87
- Average True Range (ATR)
- NOG 0.95
- GH 1.13
- MACD
- NOG -0.45
- GH 0.18
- Stochastic Oscillator
- NOG 18.93
- GH 69.88
About NOG Northern Oil and Gas Inc.
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. Company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), and the Appalachian Basin (Pennsylvania and Ohio).
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.